MCID: PST005
MIFTS: 54

Posterior Uveitis

Categories: Eye diseases, Immune diseases, Rare diseases

Aliases & Classifications for Posterior Uveitis

MalaCards integrated aliases for Posterior Uveitis:

Name: Posterior Uveitis 12 74 52 58 15 17
Uveitis, Posterior 12 74 43 71
Uveitis Posterior 54
Choroiditis 58

Characteristics:

Orphanet epidemiological data:

58
posterior uveitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:12574
MeSH 43 D015866
NCIt 49 C35111
SNOMED-CT 67 43363007 46627006
ICD10 via Orphanet 33 H30.0 H30.1 H30.2 more
UMLS via Orphanet 72 C0008526 C0042167
Orphanet 58 ORPHA280892
UMLS 71 C0042167

Summaries for Posterior Uveitis

MalaCards based summary : Posterior Uveitis, also known as uveitis, posterior, is related to choroiditis and exudative vitreoretinopathy 1, and has symptoms including eye manifestations An important gene associated with Posterior Uveitis is IL2RA (Interleukin 2 Receptor Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Fluocinolone Acetonide and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and t cells, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 74 Uveitis is the inflammation of the uvea, the pigmented layer that lies between the inner retina and the... more...

Related Diseases for Posterior Uveitis

Diseases in the Uveitis family:

Autoimmune Uveitis Posterior Uveitis
Intermediate Uveitis Infectious Anterior Uveitis
Infectious Posterior Uveitis Systemic Diseases with Anterior Uveitis
Systemic Diseases with Posterior Uveitis

Diseases related to Posterior Uveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1913)
# Related Disease Score Top Affiliating Genes
1 choroiditis 31.6 TNF SAG RBP3 MRAP IFNG CFH
2 exudative vitreoretinopathy 1 31.6 TNF RBP3 IL6
3 retinal vasculitis 31.4 SAG RBP3 MRAP CCR6
4 chorioretinitis 31.3 TNF SAG RBP3 MRAP IL6 IL2
5 multifocal choroiditis 31.2 TNF CFH
6 macular retinal edema 30.9 TNF MRAP IL6
7 retinal detachment 30.8 TNF IL6 IFNG CAPN5
8 sympathetic ophthalmia 30.7 TNF RBP3 LTA
9 iridocyclitis 30.5 TNF RBP3 MRAP IL6
10 toxoplasmosis 30.4 TNF IL6 IL5 IL4 IFNG
11 neuroretinitis 30.4 SAG MRAP IFNG
12 herpes zoster 30.4 TNF IL2 IFNG
13 neuritis 30.4 TNF IL6 IL4 IFNG
14 poems syndrome 30.3 TNF IL6 IL2
15 bacterial meningitis 30.3 TNF IL6 IFNG
16 lyme disease 30.3 TNF IL6 CFH
17 keratopathy 30.2 TNF IL4 IL1A
18 end stage renal failure 30.2 TNF IL6 IL2RA IL2
19 poliomyelitis 30.2 TNF IL4 IFNG
20 cytokine deficiency 30.1 IL9 IL5 IL13
21 chlamydia 30.1 TNF IL6 IL4 IFNG
22 panophthalmitis 30.1 SAG IFNG
23 alopecia 30.1 TNF IL4 IL2 IFNG
24 obstructive jaundice 30.1 TNF IL6 IL2
25 cone-rod dystrophy 2 30.1 TNF SAG LTA IL6 IL2
26 posterior scleritis 30.0 TNF MRAP
27 human immunodeficiency virus type 1 30.0 TNF LTA IL6 IL2 IFNG
28 measles 30.0 TNF IL6 IL2RA IL2 IFNG
29 purpura 30.0 TNF IL6 IL4
30 endocarditis 30.0 TNF IL6 IFNG
31 fungal meningitis 29.9 TNF IL6 IFNG
32 fuchs' heterochromic uveitis 29.9 MRAP IL6
33 hypopyon 29.9 RBP3 MRAP IL6
34 brain edema 29.9 IL6 IL2 IFNG
35 cutaneous lupus erythematosus 29.8 TNF IL6 IFNG
36 orchitis 29.8 TNF IL6 IL2
37 churg-strauss syndrome 29.8 TNF IL5 IL2
38 meningitis 29.8 TNF IL6 IL5 IL4 IL2 IFNG
39 mumps 29.8 TNF IL6 IL2RA IL2 IFNG
40 chronic graft versus host disease 29.8 IL2RA IL1A IFNG
41 hepatitis a 29.8 TNF IL4 IL2 IFNG
42 stomatitis 29.8 TNF IL6 IL4 IL2 IFNG
43 meningoencephalitis 29.8 TNF IL6 CCR6
44 t-cell large granular lymphocyte leukemia 29.8 IL2RB IL2RA IL2
45 complex regional pain syndrome 29.8 TNF IL6 IL2
46 aseptic meningitis 29.7 TNF IL1A IFNG
47 cardiac sarcoidosis 29.7 TNF IL5 IFNG
48 leptospirosis 29.7 TNF IL6 IL4 IL2 IFNG
49 myocarditis 29.7 TNF IL6 IL4 IL2 IFNG
50 eales disease 29.7 TNF SAG RBP3 IL6 IL4 IFNG

Graphical network of the top 20 diseases related to Posterior Uveitis:



Diseases related to Posterior Uveitis

Symptoms & Phenotypes for Posterior Uveitis

UMLS symptoms related to Posterior Uveitis:


eye manifestations

MGI Mouse Phenotypes related to Posterior Uveitis:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 CCR6 CFH IFNG IL13 IL1A IL2
2 hematopoietic system MP:0005397 10.28 CCR6 CFH IFNG IL13 IL1A IL2
3 growth/size/body region MP:0005378 10.25 CAPN5 CFH IFNG IL13 IL2 IL2RA
4 immune system MP:0005387 10.22 CAPN5 CCR6 CFH IFNG IL13 IL1A
5 cardiovascular system MP:0005385 10.19 CCR6 CFH IFNG IL1A IL2 IL2RA
6 endocrine/exocrine gland MP:0005379 10.16 IFNG IL13 IL2 IL2RA IL2RB IL4
7 digestive/alimentary MP:0005381 10.13 IFNG IL13 IL2 IL2RA IL4 IL5
8 mortality/aging MP:0010768 10 CAPN5 CFH IFNG IL13 IL2 IL27
9 liver/biliary system MP:0005370 9.91 IFNG IL2 IL2RB IL4 IL5 IL6
10 respiratory system MP:0005388 9.65 IFNG IL13 IL2 IL2RA IL4 IL5
11 vision/eye MP:0005391 9.36 CFH IFNG IL2 IL2RA IL4 IL6

Drugs & Therapeutics for Posterior Uveitis

Drugs for Posterior Uveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
8
Chlorambucil Approved Phase 4 305-03-3 2708
9
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
10
Azathioprine Approved Phase 4 446-86-6 2265
11
Infliximab Approved Phase 4 170277-31-3
12
Mycophenolic acid Approved Phase 4 24280-93-1 446541
13
Ranibizumab Approved Phase 4 347396-82-1 459903
14
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
15
Choline Approved, Nutraceutical Phase 4 62-49-7 305
16
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
17 Methylprednisolone Acetate Phase 4
18 Neuroprotective Agents Phase 4
19 Protective Agents Phase 4
20 Cyclosporins Phase 4
21 Angiogenesis Inhibitors Phase 4
22 Alkylating Agents Phase 4
23 Cathartics Phase 4
24 Laxatives Phase 4
25 Carboxymethylcellulose Sodium Phase 4
26 Nootropic Agents Phase 4
27 Cytidine Diphosphate Choline Phase 4
28 Melanocyte-Stimulating Hormones Phase 4
29 Adrenocorticotropic Hormone Phase 4
30 beta-endorphin Phase 4
31
Adalimumab Approved Phase 3 331731-18-1 16219006
32
Isoniazid Approved, Investigational Phase 3 54-85-3 3767
33
Ethambutol Approved Phase 3 74-55-5 3279 14052
34
Phenylephrine Approved Phase 3 59-42-7 6041
35
Oxymetazoline Approved, Investigational Phase 3 1491-59-4 4636
36
Atropine Approved, Vet_approved Phase 3 5908-99-6, 51-55-8 174174
37
Rifampicin Approved Phase 3 13292-46-1 5458213 5381226
38
Fluorometholone Approved, Investigational Phase 3 426-13-1 9878
39
Dipivefrin Approved Phase 3 52365-63-6 3105
40
Pyrazinamide Approved, Investigational Phase 3 98-96-4 1046
41
Tropicamide Approved, Investigational Phase 3 1508-75-4 5593
42 Antiviral Agents Phase 3
43 Interferon-alpha Phase 3
44 Interferon alpha-2 Phase 3
45 interferons Phase 3
46 Calcineurin Inhibitors Phase 3
47 Anti-Infective Agents Phase 3
48 Anti-Bacterial Agents Phase 3
49 Ophthalmic Solutions Phase 3
50 Antitubercular Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 96)
# Name Status NCT ID Phase Drugs
1 A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
2 The Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot Study Unknown status NCT01306955 Phase 4 methylorednisolone
3 Proof of Concept Study of the Effectiveness of Ozurdex in Lieu of Oral Corticosteroids for the Control of Active Intermediate and Posterior Uveitis Requiring Immunosuppressive Drug Therapy Completed NCT02049476 Phase 4 Dexamethasone pellet
4 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
5 Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
6 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
7 TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
8 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
9 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
10 A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis NIPPU Recruiting NCT03656692 Phase 4 Acthar
11 Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis Recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
12 Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema (CME) Withdrawn NCT02598869 Phase 4 Triamcinolone Acetonide
13 A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
14 A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
15 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
16 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
17 A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT02748512 Phase 3 FAI insert
18 Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis Completed NCT03097315 Phase 3
19 A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT01148225 Phase 3 adalimumab
20 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01138657 Phase 3 Prednisone;Placebo
21 A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety & Efficacy of Intravitreal Fluocinolone Acetonide (0.59 or 2.1 mg) Implant in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT00407082 Phase 2, Phase 3 fluocinolone acetonide intravitreal implant;Fluocinolone acetonide 2.1mg
22 A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
23 Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet`s Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
24 A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye Completed NCT01358266 Phase 3 DE-109 44 ug;DE-109 440 ug;DE-109 880 ug
25 A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
26 Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation Completed NCT00407121 Phase 3 Bevacizumab
27 A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye Active, not recruiting NCT01694186 Phase 3 FAI insert;Sham injection
28 A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye Active, not recruiting NCT02746991 Phase 3 Sham Injection;FAI Insert
29 Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA) Not yet recruiting NCT04117698 Phase 3 Antitubercular treatment (RIFATER ©);Ethambutol;RIFINAH ©
30 A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study Terminated NCT02375685 Phase 3
31 A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
32 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis Terminated NCT01684345 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
33 An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects With Non Infectious Intermediate-, Posterior-, or Pan-Uveitis Patients Who Each Successfully Completed Either the X052130/CL3-78989-005 (EYEGUARD™-A) or the X052131/CL3-78989-006 (EYEGUARD™-C) Study or Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133 (EYEGUARD™-US) Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
34 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment Terminated NCT01747538 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
35 A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis. Terminated NCT01032915 Phase 3 Placebo
36 A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01103024 Phase 3
37 A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
38 A Multicenter, Open-label Study to Evaluate the Long Term Clinical Use of Treatment With AIN457 in Patients Completing Clinical Trials Investigating AIN457 for the Treatment of Non-infectious Intermediate, Posterior or Panuveitis Withdrawn NCT01327664 Phase 3
39 Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Unknown status NCT01717170 Phase 1, Phase 2 Tocilizumab
40 A Multicenter, Single Sequence, Open-label Study to Assess the Tolerability, Safety, and Efficacy of 2 Weeks Oral AEB071 300 mg Twice Daily, Followed by 6 Weeks AEB071 200 mg Twice Daily in the Treatment of Patients With Macular Edema Associated With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT00615693 Phase 2 AEB071
41 Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
42 A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
43 Combination Daclizumab/Denileukin Diftitox (Ontak) Therapy for the Induction of Immune Tolerance in Non-infectious Intermediate and Posterior Uveitis Completed NCT00326508 Phase 2 Daclizumab
44 A Randomized, Active-controlled, Open-label, Multicenter proof-of Concept Study of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, Posterior-, or Panuveitis Requiring Systemic Immunosuppressive Therapy Completed NCT01526889 Phase 2 LFG316;Conventional Therapy
45 An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis Completed NCT00685399 Phase 2 AIN457;AIN 457;AIN457
46 Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome Completed NCT00035906 Phase 2 DEX PS DDS®
47 Evaluation of Birdshot RETINE CHOROIDOPATHY Treatment by Either Steroid or Interferon alpha2a Completed NCT00508040 Phase 2 interferon alpha 2a;prednisone
48 Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection) Completed NCT00470977 Phase 1, Phase 2 ranibizumab injection (0.5 mg)
49 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
50 Daclizumab for Active, Non-infectious, Sight-threatening Uveitis: A Phase II Pilot Study Completed NCT00070759 Phase 2 Daclizumab

Search NIH Clinical Center for Posterior Uveitis

Cochrane evidence based reviews: uveitis, posterior

Genetic Tests for Posterior Uveitis

Anatomical Context for Posterior Uveitis

MalaCards organs/tissues related to Posterior Uveitis:

40
Eye, Retina, T Cells, Thyroid, B Cells, Brain, Lung

Publications for Posterior Uveitis

Articles related to Posterior Uveitis:

(show top 50) (show all 1322)
# Title Authors PMID Year
1
Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. 54 61
15878055 2005
2
Serum cytokine receptor levels in noninfectious uveitis. 54 61
15746567 2005
3
Human S-antigen: peptide determinant recognition in uveitis patients. 54 61
15010290 2004
4
Human retinal S-antigen: T cell epitope mapping in posterior uveitis patients. 54 61
11263956 2001
5
Oligoclonal activation of CD4+ T lymphocytes in posterior uveitis. 54 61
7882564 1995
6
[Cellular immunoreaction to S-antigen in patients with uveitis and optic neuritis]. 54 61
8223035 1993
7
Distribution of IL-2R and CD45Ro expression on CD4+ and CD8+ T-lymphocytes in the peripheral blood of patients with posterior uveitis. 54 61
1358556 1992
8
Identification of an S-antigen-like molecule in human choroid plexus and cerebrospinal fluid. 54 61
1289136 1992
9
Ocular toxoplasmosis associated with up-regulation of miR-155-5p/miR-29c-3p and down-regulation of miR-21-5p/miR-125b-5p. 61
31945658 2020
10
Retinal vascular inflammatory and occlusive changes in infectious and non-infectious uveitis. 61
32016664 2020
11
Clinical Features of Ocular Syphilis: a Retrospective Clinical Study in an Italian Referral Centre. 61
32036734 2020
12
The Detection of Occult Retinal Vasculitis on Fluorescein Angiography in Pediatric Uveitis. 61
31708487 2020
13
Automated measurement of leakage on wide-field angiography in the assessment of retinal vasculitis. 61
32009203 2020
14
Aetiology of posterior uveitis in a tertiary centre in Finland. 61
31273927 2020
15
Vaccine-Associated Posterior Uveitis. 61
31971925 2020
16
Miliary tuberculosis and choroidal tuberculoma in a three-month old baby girl: Diagnosis and follow-up of a case. 61
31771808 2020
17
Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS) - Report 2: Pattern of Uveitis Investigations in Singapore. 61
30335550 2020
18
UNILATERAL OPTIC NEURITIS AND CENTRAL RETINAL VASCULITIS DUE TO OCULAR SYPHILIS. 61
28816862 2020
19
Multimodal imaging patterns of posterior syphilitic uveitis: a review of the literature, laboratory evaluation and treatment. 61
31927680 2020
20
Sexual dysfunction in Behçet's syndrome. 61
31595309 2020
21
Demographic and Clinical Features of Pediatric Uveitis in Israel. 61
30332547 2020
22
COMBINED VITRECTOMY WITH INTRAVITREAL DEXAMETHASONE IMPLANT FOR REFRACTORY MACULAR EDEMA SECONDARY TO DIABETIC RETINOPATHY, RETINAL VEIN OCCLUSION, AND NONINFECTIOUS POSTERIOR UVEITIS. 61
30312262 2020
23
Relationship of Epiretinal Membrane Formation and Macular Edema Development in a Large Cohort of Uveitic Eyes. 61
31961201 2020
24
Ocular Manifestations In Late Onset Behçet's Disease. 61
31994475 2020
25
Contribution of HLA-B*51:01 and -A*26:01 to Behçet's disease and their clinical association in Thai patients. 61
31944588 2020
26
Usefulness of aqueous and vitreous humor analysis in infectious uveitis. 61
31994615 2020
27
Toxoplasmosis and behavioural changes. 61
31980266 2020
28
Retinal vessel oxygen saturation is affected in uveitis associated with Vogt-Koyanagi-Harada disease. 61
30798260 2019
29
Primary Ocular Toxoplasmosis Presenting to Uveitis Services in a Non-endemic Setting. 61
31833248 2019
30
[Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis]. 61
31818505 2019
31
Visual Acuity Outcome over Time in Non-Infectious Uveitis. 61
31821051 2019
32
Induction of ocular Behçet's disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years. 61
31856941 2019
33
Bartonella henselae- and quintana-associated uveitis: a case series and approach of a potentially severe disease with a broad spectrum of ocular manifestations. 61
30852734 2019
34
SELF-INFLICTED LASER-INDUCED MACULOPATHY MASQUERADING AS POSTERIOR UVEITIS IN A PATIENT WITH SUSPECTED IgG4-RELATED DISEASE. 61
31725490 2019
35
Dexamethasone Intravitreal Implant Injection in Eyes with Comorbid Hypotony. 61
31371197 2019
36
Lymphocyte Immunophenotyping and CD4/CD8 Ratio in Cerebrospinal Fluid for the Diagnosis of Sarcoidosis-related Uveitis. 61
31671003 2019
37
[Epidemiologic and etiologic patterns of uveitis in a University Hospital]. 61
31164299 2019
38
Characteristics of Behcet's Disease in the American Southwest. 61
30952423 2019
39
Approach to ocular toxoplasmosis including pregnant women. 61
31313714 2019
40
High-Resolution Imaging of Retinal Vasculitis by Flood Illumination Adaptive Optics Ophthalmoscopy: A Follow-up Study. 61
31573376 2019
41
Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis. 61
31663454 2019
42
Optical coherence tomography diagnostic signs in posterior uveitis. 61
31513851 2019
43
Spectral optical coherence tomography findings in an adult patient with syphilitic bilateral posterior uveitis and unilateral punctate inner retinitis. 61
31211286 2019
44
Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients. 61
30959067 2019
45
Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. 61
31607412 2019
46
Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial. 61
31503307 2019
47
Vision loss with pembrolizumab treatment: A report of two cases. 61
30997872 2019
48
A sarcoidosis-lymphoma syndrome revealed by hypopituitarism. 61
31600729 2019
49
Intravitreal sustained-release dexamethasone implant for the treatment of persistent cystoid macular edema in ocular syphilis. 61
31436209 2019
50
Use of Immunomodulatory Drugs at a Uveitis Clinic. 61
29132749 2019

Variations for Posterior Uveitis

Expression for Posterior Uveitis

Search GEO for disease gene expression data for Posterior Uveitis.

Pathways for Posterior Uveitis

Pathways related to Posterior Uveitis according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 TNF LTA IL9 IL6 IL5 IL4
2
Show member pathways
13.93 TNF LTA IL9 IL6 IL5 IL4
3
Show member pathways
13.74 TNF LTA IL9 IL6 IL5 IL4
4
Show member pathways
13.64 TNF LTA IL9 IL6 IL5 IL4
5
Show member pathways
13.5 TNF LTA IL9 IL6 IL5 IL4
6
Show member pathways
13.43 TNF LTA IL9 IL6 IL5 IL4
7
Show member pathways
13.37 TNF LTA IL9 IL6 IL5 IL4
8
Show member pathways
13.27 TNF IL4 IL2RB IL2RA IL2 IL1A
9
Show member pathways
13.04 TNF IL6 IL4 IL2RB IL2RA IL2
10 12.99 IL6 IL5 IL4 IL2RB IL2RA IL2
11
Show member pathways
12.95 TNF IL6 IL2RB IL2RA IL2 IL1A
12
Show member pathways
12.94 TNF LTA IL9 IL6 IL5 IL4
13
Show member pathways
12.93 TNF LTA IL9 IL6 IL4 IL2RB
14
Show member pathways
12.8 TNF LTA IL9 IL6 IL2 IL1A
15
Show member pathways
12.74 TNF IL9 IL6 IL5 IL4 IL2
16
Show member pathways
12.71 TNF IL6 IL5 IL4 IL2RB IL2RA
17
Show member pathways
12.69 TNF IL4 IL2RA IL2 IFNG
18 12.69 TNF IL4 IL2RB IL2RA IL2 IFNG
19
Show member pathways
12.58 IL5 IL2RA IL2 IL1A IL13 CAPN5
20 12.49 TNF LTA IL6 IL2RB IL2RA IL2
21
Show member pathways
12.48 TNF IL6 IL5 IL4 IL13 IFNG
22
Show member pathways
12.48 TNF LTA IL6 IL2RB IL2RA IL2
23
Show member pathways
12.44 TNF IL6 IL4 IL2 IFNG
24
Show member pathways
12.42 IL9 IL6 IL5 IL4 IL2RB IL2RA
25
Show member pathways
12.31 TNF IL4 IL1A IFNG
26 12.29 TNF IL6 IL1A IFNG
27
Show member pathways
12.27 TNF LTA IL9 IL6 IL5 IL4
28
Show member pathways
12.24 TNF IL6 IL4 IFNG
29 12.23 TNF IL6 IL1A IL13
30
Show member pathways
12.21 TNF LTA IL6 IL27 IL2 IFNG
31
Show member pathways
12.2 IL5 IL2RB IL2RA IL2
32
Show member pathways
12.19 TNF IL6 IL4 IL13 IFNG
33
Show member pathways
12.17 IL5 IL2RA IL2 IL1A IL13
34 12.17 TNF IL6 IL4 IL2 IL1A IFNG
35
Show member pathways
12.14 IL2RB IL2RA IL2 IFNG
36 12.13 TNF IL6 IL4 IL1A IL13
37
Show member pathways
12.13 IL4 IL2RB IL2RA IL2 IFNG
38 12.1 TNF IL6 IL5 IL4 IL2RB IL2RA
39 12.06 TNF IL6 IL5 IL4 IL2RA IL1A
40 12.04 IL6 IL2RB IL2RA IL2 IFNG
41 11.98 TNF IL6 IL1A IFNG
42 11.96 IL6 IL5 IL4 IL2 IL13 IFNG
43
Show member pathways
11.91 TNF IL5 IL4 IL2RA IL2 IFNG
44
Show member pathways
11.88 LTA IL4 IL2RB IL2RA IL2
45 11.87 TNF IL6 IL2 IFNG
46 11.86 TNF IL6 IL4 IL2 IL13 IFNG
47
Show member pathways
11.84 TNF IL6 IL2 IL1A IFNG
48 11.83 TNF IL6 IL5 IL4 IL13
49 11.82 IL6 IL1A IFNG
50
Show member pathways
11.82 TNF IL2RB IL2RA IL2 IFNG

GO Terms for Posterior Uveitis

Cellular components related to Posterior Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TNF RBP3 LTA IL9 IL6 IL5
2 external side of plasma membrane GO:0009897 9.65 TNF IL2RB IL2RA IL13 CCR6
3 extracellular space GO:0005615 9.44 TNF RBP3 LTA IL9 IL6 IL5
4 interleukin-2 receptor complex GO:0005893 9.16 IL2RB IL2RA

Biological processes related to Posterior Uveitis according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10 TNF IL6 IL4 IL1A IL13 IFNG
2 MAPK cascade GO:0000165 9.97 TNF IL5 IL2RB IL2RA IL2
3 inflammatory response GO:0006954 9.87 TNF IL9 IL6 IL5 IL27 IL1A
4 positive regulation of interleukin-6 production GO:0032755 9.82 TNF IL6 IL1A
5 positive regulation of smooth muscle cell proliferation GO:0048661 9.82 TNF IL6 IL13
6 positive regulation of phagocytosis GO:0050766 9.8 TNF IL2RB IFNG
7 positive regulation of interferon-gamma production GO:0032729 9.79 TNF LTA IL2
8 positive regulation of JAK-STAT cascade GO:0046427 9.76 TNF IL6 IL5
9 positive regulation of T cell proliferation GO:0042102 9.76 IL6 IL4 IL2RA IL2
10 microglial cell activation GO:0001774 9.75 TNF IL13 IFNG
11 positive regulation of T cell differentiation GO:0045582 9.69 IL4 IL2RA IL2
12 positive regulation of neuroinflammatory response GO:0150078 9.67 TNF IL6
13 positive regulation of podosome assembly GO:0071803 9.67 TNF IL5
14 positive regulation of chemokine biosynthetic process GO:0045080 9.67 TNF IFNG
15 positive regulation of glial cell proliferation GO:0060252 9.67 TNF LTA IL6
16 positive regulation of B cell proliferation GO:0030890 9.67 IL5 IL4 IL2 IL13
17 negative regulation of amyloid-beta clearance GO:1900222 9.66 TNF IFNG
18 positive regulation of isotype switching to IgG isotypes GO:0048304 9.66 IL4 IL2
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IL4 IFNG
20 negative regulation of lipid storage GO:0010888 9.65 TNF IL6
21 regulation of regulatory T cell differentiation GO:0045589 9.65 IL2RA IL2 IFNG
22 humoral immune response GO:0006959 9.65 TNF LTA IL6 IFNG CCR6
23 negative regulation of lymphocyte proliferation GO:0050672 9.64 IL2RA IL2
24 neuroinflammatory response GO:0150076 9.63 IL4 IFNG
25 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.63 TNF LTA
26 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 TNF IL6 IL4 IL2 IL13 IFNG
27 positive regulation of cellular respiration GO:1901857 9.61 IL4 IFNG
28 negative regulation of complement-dependent cytotoxicity GO:1903660 9.61 IL4 IL13
29 positive regulation of immunoglobulin secretion GO:0051024 9.61 IL6 IL5 IL2
30 cytokine-mediated signaling pathway GO:0019221 9.61 TNF IL6 IL5 IL4 IL2RB IL2RA
31 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.6 TNF IFNG
32 regulation of T cell homeostatic proliferation GO:0046013 9.59 IL2RA IL2
33 interleukin-2-mediated signaling pathway GO:0038110 9.58 IL2RB IL2RA IL2
34 positive regulation of vitamin D biosynthetic process GO:0060557 9.56 TNF IFNG
35 positive regulation of nitrogen compound metabolic process GO:0051173 9.55 TNF IFNG
36 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.54 TNF LTA
37 immune response GO:0006955 9.4 TNF LTA IL9 IL6 IL5 IL4

Molecular functions related to Posterior Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.36 TNF LTA IL9 IL6 IL5 IL4
2 growth factor activity GO:0008083 9.35 IL9 IL6 IL5 IL4 IL2
3 cytokine receptor binding GO:0005126 9.33 IL9 IL4 IL13
4 interleukin-2 binding GO:0019976 9.32 IL2RB IL2RA
5 interleukin-2 receptor activity GO:0004911 9.26 IL2RB IL2RA

Sources for Posterior Uveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....